Abiopharma

Tyndall Mark Anthony 🟡 adjusted position in 2.1K shares (1 derivative) of Keenova Therapeutics plc (NONE) Transaction Date: Jan 01, 2026 | Filing ID: 000784

ONeill Hugh Paul 🟡 adjusted position in 1.1K shares (1 derivative) of Keenova Therapeutics plc (NONE) Transaction Date: Jan 01, 2026 | Filing ID: 000783

Director Olafsson Sigurdur O 🟡 adjusted position in 16.9K shares (1 derivative) of Keenova Therapeutics plc (NONE) Transaction Date: Jan 01, 2026 | Filing ID: 000782

Nielsen Henriette 🟡 adjusted position in 2.4K shares (1 derivative) of Keenova Therapeutics plc (NONE) Transaction Date: Jan 01, 2026 | Filing ID: 000781

French Lisa 🟡 adjusted position in 2.0K shares (1 derivative) of Keenova Therapeutics plc (NONE) Transaction Date: Jan 01, 2026 | Filing ID: 000780

Saia John G. 🟡 adjusted position in 17.8K shares (6 derivative) of Guardant Health, Inc. (GH) at $102.14 ($1.0M) Transaction Date: Jan 01, 2026 | Filing ID: 000002

Monroe Terilyn J. 🟡 adjusted position in 7.5K shares (2 derivative) of Guardant Health, Inc. (GH) at $102.14 Transaction Date: Jan 01, 2026 | Filing ID: 000002

Director Dorton Katina 🟡 adjusted position in 2.0K shares (2 derivative) of Keenova Therapeutics plc (NONE) Transaction Date: Jan 01, 2026 | Filing ID: 000779

Alpern Robert J 🟢 acquired 62 shares (1 derivative) of ABBOTT LABORATORIES (ABT) Transaction Date: Dec 31, 2025 | Filing ID: 000004

Director Schlanger David J 🔴 sold 2.2K shares of Progyny, Inc. (PGNY) at $25.68 Transaction Date: Jan 02, 2026 | Filing ID: 000006

Director Bisaro Paul 🟡 adjusted position in 3.3K shares (2 derivative) of Keenova Therapeutics plc (NONE) Transaction Date: Jan 01, 2026 | Filing ID: 000777

Kalia Kumud 🟡 adjusted position in 22.2K shares (6 derivative) of Guardant Health, Inc. (GH) at $102.14 Transaction Date: Jan 01, 2026 | Filing ID: 000002

Silva Raul R. 🟢 acquired 6.6K shares (1 derivative) of Cingulate Inc. (CING) at $4.34 Transaction Date: Dec 31, 2025 | Filing ID: 000455

QURE Investigation: Investors Encouraged to Contact Kirby McInerney LLP

ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP